TrialArthritis research & therapy2007

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.

Piotr Krzeski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.